Skip to main content
Premium Trial:

Request an Annual Quote

Great Basin Files for Public Offering of Stock, Warrants

NEW YORK (GenomeWeb) – Great Basin Scientific today filed a prospectus for an offering of units comprising its Series E convertible preferred stock and Series C warrants. 

Dawson James Securities is the sole book running manager on the proposed offering. Great Basin has not priced the offering or said how many units it plans to offer. Net proceeds will be used to fund the company's operations, including the completion of planned clinical trials and a filing with the US Food and Drug Administration for its Staph ID/R and Shiga toxin-producing Escherichia coli diagnostic tests, the company said in its document filed with the US Securities and Exchange Commission.

Additionally, proceeds will go toward R&D, sales and marketing, manufacturing of instruments, automation of the firm's manufacturing facility, and increasing its manufacturing capacity, Great Basin said.

Great Basin went public in late October raising about $6.4 million in net proceeds.  


The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.